The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
Immuno Cure Holding (HK) Limited is a biotechnology group focusing on its patented technology platforms for the research and development of immunotherapy for cancers, inflammatory and infectious diseases. The patented technology platforms comprise a PD-1 based DNA vaccine technology platform to target various infectious diseases and cancers as well as an anti-PD-1 isoform antibody to suppress inflammation.
The Group is based in Hong Kong Science Park and Shenzhen with an experienced management team and a group of partners with expertise in the DNA vaccine ecosystem, including R&D institution, CDMO, electroporation device technology, DNA vaccine manufacturing process technology, CRO and GMP manufacturer.
Utilizing the two technology platforms, the Group has developed a list of pipelines for the HIV and cancer treatments as well as COVID-19 prevention.